Analysis and characterization of aggregation of a therapeutic Fc-fusion protein

Journal of Pharmaceutical and Biomedical Analysis

Volumn 72, Issue , 2013, Pages 59-64

  Wang, Tian ^a   Fodor, Szilan ^a   Hapuarachchi, Suminda ^a   Jiang, Xinzhao Grace ^a   Chen, Ken ^a   Apostol, Izydor ^a   Huang, Gang ^a  

^a AMGEN INC   (United States)

Author keywords

Fc fusion protein; Free thiols; Partially frozen; Protein aggregation; Protein stability

Indexed keywords

FC FUSION PROTEIN; HYBRID PROTEIN; THIOL DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; COLUMN CHROMATOGRAPHY; CROSS LINKING; ESCHERICHIA COLI; FREEZING; LIQUID CHROMATOGRAPHY; LIQUID CHROMATOGRAPHY MASS SPECTROMETRY; MASS SPECTROMETRY; PH; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN PURIFICATION; PROTEIN REFOLDING; PROTEIN STABILITY; SIZE EXCLUSION HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

CHROMATOGRAPHY, LIQUID; ESCHERICHIA COLI; FREEZING; HYDROGEN-ION CONCENTRATION; IMMUNOGLOBULIN FC FRAGMENTS; INCLUSION BODIES; MASS SPECTROMETRY; PROTEIN STABILITY; RECOMBINANT FUSION PROTEINS; SALTS; SULFHYDRYL COMPOUNDS; TEMPERATURE;

EID: 84869053296     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2012.09.010     Document Type: Article

References (35)

1. Volkin D.B., March H., Middaugh C.R. Degradative covalent reactions important to protein stability. Mol. Biotechnol. 1997, 8:105-122.
2. Manning M.C., Patel K., Borchard R.T. Stability of protein pharmaceuticals. Pharm. Res. 1989, 6:903-918.
3. Wang W. Instability stabilization, and formulation of liquid protein pharmaceuticals. Int. J. Pharm. 1999, 185:129-188.
4. Rosenberg A.S. Effect of protein aggregates: an immunological perspective. AAPS J. 2006, 8:E501-E507.
5. Fradkin A.H., Carpenter J.F., Randolph T.W. Immunogenicity of aggregates of recombinant human growth hormone in mouse models. J. Pharm. Sci. 2009, 98:3247-3264.
6. Hermeling S., Crommelin D., Schellekens H., Jiskoot W. Structure-immunogenicity relationships of therapeutic proteins. Pharm. Res. 2004, 21:897-903.
7. Franey H., Brych S.R., Kolvenbach C.G., Rajan R.S. Increased aggregation propensity of IgG2 subclass over IgG1: role of conformational changes and covalent character in isolated aggregates. Protein Sci. 2010, 19:1601-1615.
8. Schweers O., Mandelkow E.M., Biernat J., Mandelkow E. Oxidation of cysteine-322 in the repeat domain of microtubule-associated protein tau controls the in vitro assembly of paired helical filaments. Proc. Natl. Acad. Sci. U.S.A. 1995, 92:8463-8467.
9. Brych S.R., Gokarn Y.R., Hultgen H., Stevenson R.J., Rajan R., Matsumura M. Characterization of antibody aggregation: role of buried unpaired cysteines in particle formation. J. Pharm. Sci. 2010, 99:764-781.
10. Banks D.D., Gadgil H.S., Pipes G.D., Bondarenko P.V., Hobbs V., Scavezze J.L., Kim J., Jiang X.-R., Mukku V., Dillon T.M. Removal of cysteinylation from an unpaired sulfhydryl in the variable region of a recombinant monoclonal IgG1 antibody improves homogeneity stability, and biological activity. J. Pharm. Sci. 2008, 97:764-779.
11. Gadgil H.S., Bondarenko P.V., Pipes G.D., Dillon T.M., Banks D., Abel J., Kleemann G.R., Treuheit M.J. Identification of cysteinylation of a free cysteine in the Fab region of a recombinant monoclonal IgG1 antibody using Lys-C limited proteolysis coupled with LC/MS analysis. Anal. Biochem. 2006, 355:165-174.
12. Cromwell M.E.M., Hilario E., Jacobson F. Protein aggregation and bioprocessing. AAPS J. 2006, 8:E572-E579.
13. Mahler H.-C., Friess W., Grauschopf U., Kiese S. Protein aggregation: pathways, induction factors and analysis. J. Pharm. Sci. 2009, 98:2909-2934.
14. Joubert M.K., Luo Q., Nashed-Samuel Y., Wypych J., Narhi L.O. Classification and characterization of therapeutic antibody aggregates. J. Biol. Chem. 2011, 286:25118-25133.
15. Wang W. Protein aggregation and its inhibition in biopharmaceutics. Int. J. Pharm. 2005, 289:1-30.
16. Zhang Z. De novo peptide sequencing based on a divide-and-conquer algorithm and peptide tandem spectrum simulation. Anal. Chem. 2004, 76:6374-6383.
17. Kandegedara A., Rorabacher D.B. Noncomplexing tertiary amines as better buffers covering the range of pH 3-11, temperature dependence of their acid dissociation constant. Anal. Chem. 1999, 71:3140-3144.
18. Rey L. Glimpses into the realm of freeze-drying: fundamental issues. Freeze-Drying/Lyophilization of Pharmaceutical and Biological Products 2007, 1-32. Informa Healthcare USA, Inc., New York, NY. L. Rey, J.C. May (Eds.).
19. Schmid G., Lüdemann H.-D., Jaenicke R. Oxidation of sulfhydryl groups in lactate dehydrogenase under high hydrostatic pressure. Eur. J. Biochem. 1978, 86:219-224.
20. Kolthoff I.M., Anastasi A. Reactivity of sulfhydryl and disulfide in proteins. III. Oxidation with ferricyanide of sulfhydryl in native and denatured bovine serum albumin. J. Am. Chem. Soc. 1958, 80:4248-4250.
21. Weissman J., Kim P. Reexamination of the folding of BPTI: predominance of native intermediates. Science 1991, 253:1386-1393.
22. Harris L.J., Larson S.B., Hasel K.W., McPherson A. Refined structure of an intact IgG2a monoclonal antibody. Biochemistry 1997, 36:1581-1597.
23. Saphire E.O., Parren P.W.H.I., Pantophlet R., Zwick M.B., Morris G.M., Rudd P.M., Dwek R.A., Stanfield R.L., Burton D.R., Wilson I.A. Crystal structure of a neutralizing human IgG against HIV-1: a template for vaccine design. Science 2001, 293:1155-1159.
24. Franks F. Chapter 14, storage stabilization of proteins. Protein Biotechnology, Isolation Characterization and Stability 1993, 489-531. The Humana Press Inc., Totowa, NJ. F. Franks (Ed.).
25. Franks F. Freeze-drying of bioproducts: putting principles into practice. Eur. J. Pharm. Biopharm. 1998, 45:221-229.
26. Crowe J.H., Carpenter J.F., Crowe L.M. The role of vitrification in anhydrobiosis. Annu. Rev. Physiol. 1998, 60:73-103.
27. Carpenter J.F., Pikal M.J., Chang B.S., Randolph T.W. Rational design of stable lyophilized protein formulations: some practical advice. Pharm. Res. 1997, 14:969-975.
28. Cocks F.H., Brower W.E. Phase diagram relationships in cryobiology. Cryobiology 1974, 11:340-358.
29. Liu J. Physical characterization of pharmaceutical formulations in frozen and freeze-dried solid states: techniques and applications in freeze-drying development. Pharm. Dev. Technol. 2006, 11:3-28.
30. Kararli T.T., Hurlbut J.B., Needham T.E. Glass-rubber transitions of cellulosic polymers by dynamic mechanical analysis. J. Pharm. Sci. 1990, 79:845-848.
31. Duddu S.P., Sokoloski T.D. Dielectric analysis in the characterization of amorphous pharmaceutical solids. 1. Molecular mobility in poly(vinylpyrrolidone)-water systems in the glassy state. J. Pharm. Sci. 1995, 84:773-776.
32. Scopes R.K. Separation by precipitation. Protein Purification: Principles and Practice 1994, 71-84. Springer Science+Business Media, LLC., New York, NY. R.K. Scopes (Ed.).
33. Builder S.E. Chapter 2, principles of HIC. Hydrophobic Interaction Chromatography, Principles and Methods 1999, 11-18. Amersham Pharmacia Biotech UK Limited, Buckinghamshire, England. S.E. Builder (Ed.).
34. Arakawa T., Timasheff S.N. Preferential interactions of proteins with salts in concentrated solutions. Biochemistry 1982, 21:6545-6552.
35. Melander W., Horváth C. Salt effect on hydrophobic interactions in precipitation and chromatography of proteins: an interpretation of the lyotropic series. Arch. Biochem. Biophys. 1977, 183:200-215.